Retatrutide is a next-generation triple agonist peptide that simultaneously activates GLP-1, GIP and GCG receptors — producing up to 24% body weight reduction in Phase 2 trials. Here’s exactly how it works.
Retatrutide is a next-generation triple agonist peptide that simultaneously activates GLP-1, GIP and GCG receptors — producing up to 24% body weight reduction in Phase 2 trials. Here’s exactly how it works.
Français du Canada 
English 
Deutsch 
Español 
Español de México 
English (Australia)